Anacor Pharmaceutica (ANAC) 53.45 $ANAC
Anacor Pharmaceuticals, Inc. Announces Pricing of Offering of $250 Million of 2.00% Convertible Senior Notes Due 2023
BusinessWire - Thu Mar 31, 7:45PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 2.00% Convertible Senior Notes due 2023 (the "Convertible Notes"
in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Anacor also granted to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $37,500,000 aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. The offering of the Convertible Notes is expected to close on April 6, 2016, subject to customary closing conditions.
ANAC: 53.45 (-5.21)
Anacor Pharmaceuticals, Inc. Announces Proposed Offering of $250 Million of Convertible Senior Notes Due 2023
BusinessWire - Wed Mar 30, 3:01PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) announced today that it intends to offer, subject to market and other considerations, $250,000,000 aggregate principal amount of Convertible Senior Notes due 2023 (the "Convertible Notes" in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Anacor also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $37,500,000 aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any.
ANAC: 53.45 (-5.21)
Sunesis Pharmaceuticals Appoints Geoffrey Parker to the Board of Directors
GlobeNewswire - Mon Mar 28, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Geoffrey Parker has been appointed to the Sunesis Board of Directors. Mr. Parker brings over 30 years of finance and executive leadership experience to the Board including, most recently, serving as Executive Vice President and Chief Financial Officer of Anacor Pharmaceuticals, Inc., which he joined in 2010 at the time of its initial public offering. Sunesis also announced that Helen Kim stepped down from her position as a Director.
SNSS: 0.54 (-0.01), ANAC: 53.45 (-5.21)
Anacor Pharmaceuticals Announces FDA Acceptance of NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis
BusinessWire - Tue Mar 22, 7:30AM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Anacor's New Drug Application (NDA) seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. The Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA's review is January 7, 2017.
ANAC: 53.45 (-5.21)
Weakness Seen in Anacor Pharmaceuticals (ANAC) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Fri Mar 18, 8:00AM CDT
Anacor Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
ADHD: 3.79 (+0.17), ANAC: 53.45 (-5.21)
Anacor Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care Conference
BusinessWire - Thu Mar 03, 3:00PM CST
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that the company's management team will present at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9, 2016 at 9:20 a.m. ET in Boston, Massachusetts. The event will be webcast live and may be accessed under "Events and Presentations" on the Investors page of Anacor's website at www.anacor.com. A replay will also be available for three months following the presentation.
ANAC: 53.45 (-5.21)
Psoriasis Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/6tv9lw/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasisand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - PsoriasisOverview - Therapeutics Development - Pipeline Products for Psoriasis- Overview - Pipeline Products for Psoriasis- Comparative Analysis - Psoriasis- Therapeutics under Development by Companies - Psoriasis- Therapeutics under Investigation by Universities/Institutes - Psoriasis- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Psoriasis- Products under Development by Companies - Psoriasis- Products under Investigation by Universities/Institutes - Psoriasis- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 3SBio Inc. - 4SC AG - Abeome Corporation - AbGenomics International, Inc. - ADC Therapeutics Sarl - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - AlbireoPharma - Allozyne, Inc. - Almirall, S.A. - Amgen Inc. - Anacor Pharmaceuticals, Inc. - AnaptysBio, Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca Plc - Athenex, Inc. - Aurigene Discovery Technologies Limited - Avesthagen Limited - Avexxin AS - Basilea Pharmaceutica AG - BIOCAD - Biocon Limited - BioLingus AG - BioMAS Ltd. - Bionomics Limited - Bionovis SA - Boehringer Ingelheim GmbH - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Can-Fite BioPharma Ltd. - Celgene Corporation - Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/6tv9lw/psoriasis
AMGN: 149.93 (+0.45), BMY: 63.88 (+0.44), CANF: 2.79 (+0.08), ARGS: 6.40 (-1.49), AZN: 28.16 (-0.16), ANAC: 53.45 (-5.21), ARNA: 1.97 (+0.06), CELGZ: 1.31 (+0.11)
This Trade Explains the Current Market
at The Street - Wed Feb 03, 9:51AM CST
The shifting momentum of asset classes is signaling a changing economic landscape.
ANAC: 53.45 (-5.21), MUX: 1.88 (-0.02)
Hypersensitivity Pipeline Review 2015
M2 - Mon Feb 01, 8:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/42dhk8/hypersensitivity) has announced the addition of the "Hypersensitivity - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypersensitivity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypersensitivity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hypersensitivity Overview - Therapeutics Development - Pipeline Products for Hypersensitivity - Overview - Pipeline Products for Hypersensitivity - Comparative Analysis - Hypersensitivity - Therapeutics under Development by Companies - Hypersensitivity - Therapeutics under Investigation by Universities/Institutes - Hypersensitivity - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypersensitivity - Products under Development by Companies - Hypersensitivity - Products under Investigation by Universities/Institutes - Hypersensitivity - Companies Involved in Therapeutics Development - Anacor Pharmaceuticals, Inc. - Eisai Co., Ltd. - Ensemble Therapeutics Corporation - F. Hoffmann-La Roche Ltd. - JW Pharmaceutical Corporation - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/42...ensitivity
ANAC: 53.45 (-5.21)
Leishmaniasis (Kala-Azar) - Pipeline Review 2015
M2 - Fri Jan 29, 9:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/4vk3jg/leishmaniasis) has announced the addition of the "Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Leishmaniasis (Kala-Azar) Overview - Therapeutics Development - Pipeline Products for Leishmaniasis (Kala-Azar) - Overview - Pipeline Products for Leishmaniasis (Kala-Azar) - Comparative Analysis - Leishmaniasis (Kala-Azar) - Therapeutics under Development by Companies - Leishmaniasis (Kala-Azar) - Therapeutics under Investigation by Universities/Institutes - Leishmaniasis (Kala-Azar) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Leishmaniasis (Kala-Azar) - Products under Development by Companies - Leishmaniasis (Kala-Azar) - Products under Investigation by Universities/Institutes - Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development Companies Mentioned: - Advinus Therapeutics Ltd. - Anacor Pharmaceuticals, Inc. - BioLingus AG - Dafra Pharma International Ltd. - iCo Therapeutics Inc. - Merck KGaA - Mologen AG - Nanomerics Ltd - Sanofi - Takeda Pharmaceutical Company Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/4v...shmaniasis
ANAC: 53.45 (-5.21)
BUYINS.NET: EUFN, CLDT, FN, QLIK, ANAC, ELA Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Jan 19, 6:36AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Ishares MSCI Europe Financials Sector Index Fund (NASDAQ:EUFN), Chatham Lodging Trust (NYSE:CLDT), First National Financial Services Ltd (NYSE:FN), Qlik Technologies Inc (NASDAQ:QLIK), Anacor Pharmaceuticals Inc (NASDAQ:ANAC), (NYSE:ELA) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
CLDT: 21.43 (+0.18), ELA: 25.28 (unch), FN: 32.35 (-0.24), QLIK: 28.92 (+0.39), EUFN: 17.91 (-0.10), ANAC: 53.45 (-5.21)
6 Drug Stocks That Look to Beat the Market in 2016
Zacks Equity Research - Zacks Investment Research - Mon Jan 18, 3:50PM CST
Don't miss these drug stocks that look to beat the market in 2016.
UTHR: 111.43 (+1.49), PFE: 29.64 (-0.43), AERI: 12.16 (+0.02), ANAC: 53.45 (-5.21), OHRP: 3.21 (+0.05), INFI: 5.27 (+0.12), PCRX: 52.98 (+2.12)
Anacor Pharmaceuticals, Inc. Announces Pricing of Offering of $250 Million of 2.00% Convertible Senior Notes Due 2023
BusinessWire - Thu Mar 31, 7:45PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 2.00% Convertible Senior Notes due 2023 (the "Convertible Notes"
in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Anacor also granted to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $37,500,000 aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. The offering of the Convertible Notes is expected to close on April 6, 2016, subject to customary closing conditions. ANAC: 53.45 (-5.21)
Anacor Pharmaceuticals, Inc. Announces Proposed Offering of $250 Million of Convertible Senior Notes Due 2023
BusinessWire - Wed Mar 30, 3:01PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) announced today that it intends to offer, subject to market and other considerations, $250,000,000 aggregate principal amount of Convertible Senior Notes due 2023 (the "Convertible Notes"
in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Anacor also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $37,500,000 aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. ANAC: 53.45 (-5.21)
Sunesis Pharmaceuticals Appoints Geoffrey Parker to the Board of Directors
GlobeNewswire - Mon Mar 28, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Geoffrey Parker has been appointed to the Sunesis Board of Directors. Mr. Parker brings over 30 years of finance and executive leadership experience to the Board including, most recently, serving as Executive Vice President and Chief Financial Officer of Anacor Pharmaceuticals, Inc., which he joined in 2010 at the time of its initial public offering. Sunesis also announced that Helen Kim stepped down from her position as a Director.
SNSS: 0.54 (-0.01), ANAC: 53.45 (-5.21)
Anacor Pharmaceuticals Announces FDA Acceptance of NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis
BusinessWire - Tue Mar 22, 7:30AM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Anacor's New Drug Application (NDA) seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. The Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA's review is January 7, 2017.
ANAC: 53.45 (-5.21)
Weakness Seen in Anacor Pharmaceuticals (ANAC) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Fri Mar 18, 8:00AM CDT
Anacor Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
ADHD: 3.79 (+0.17), ANAC: 53.45 (-5.21)
Anacor Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care Conference
BusinessWire - Thu Mar 03, 3:00PM CST
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that the company's management team will present at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9, 2016 at 9:20 a.m. ET in Boston, Massachusetts. The event will be webcast live and may be accessed under "Events and Presentations" on the Investors page of Anacor's website at www.anacor.com. A replay will also be available for three months following the presentation.
ANAC: 53.45 (-5.21)
Psoriasis Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/6tv9lw/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasisand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - PsoriasisOverview - Therapeutics Development - Pipeline Products for Psoriasis- Overview - Pipeline Products for Psoriasis- Comparative Analysis - Psoriasis- Therapeutics under Development by Companies - Psoriasis- Therapeutics under Investigation by Universities/Institutes - Psoriasis- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Psoriasis- Products under Development by Companies - Psoriasis- Products under Investigation by Universities/Institutes - Psoriasis- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 3SBio Inc. - 4SC AG - Abeome Corporation - AbGenomics International, Inc. - ADC Therapeutics Sarl - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - AlbireoPharma - Allozyne, Inc. - Almirall, S.A. - Amgen Inc. - Anacor Pharmaceuticals, Inc. - AnaptysBio, Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca Plc - Athenex, Inc. - Aurigene Discovery Technologies Limited - Avesthagen Limited - Avexxin AS - Basilea Pharmaceutica AG - BIOCAD - Biocon Limited - BioLingus AG - BioMAS Ltd. - Bionomics Limited - Bionovis SA - Boehringer Ingelheim GmbH - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Can-Fite BioPharma Ltd. - Celgene Corporation - Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/6tv9lw/psoriasis
AMGN: 149.93 (+0.45), BMY: 63.88 (+0.44), CANF: 2.79 (+0.08), ARGS: 6.40 (-1.49), AZN: 28.16 (-0.16), ANAC: 53.45 (-5.21), ARNA: 1.97 (+0.06), CELGZ: 1.31 (+0.11)
This Trade Explains the Current Market
at The Street - Wed Feb 03, 9:51AM CST
The shifting momentum of asset classes is signaling a changing economic landscape.
ANAC: 53.45 (-5.21), MUX: 1.88 (-0.02)
Hypersensitivity Pipeline Review 2015
M2 - Mon Feb 01, 8:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/42dhk8/hypersensitivity) has announced the addition of the "Hypersensitivity - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypersensitivity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypersensitivity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hypersensitivity Overview - Therapeutics Development - Pipeline Products for Hypersensitivity - Overview - Pipeline Products for Hypersensitivity - Comparative Analysis - Hypersensitivity - Therapeutics under Development by Companies - Hypersensitivity - Therapeutics under Investigation by Universities/Institutes - Hypersensitivity - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypersensitivity - Products under Development by Companies - Hypersensitivity - Products under Investigation by Universities/Institutes - Hypersensitivity - Companies Involved in Therapeutics Development - Anacor Pharmaceuticals, Inc. - Eisai Co., Ltd. - Ensemble Therapeutics Corporation - F. Hoffmann-La Roche Ltd. - JW Pharmaceutical Corporation - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/42...ensitivity
ANAC: 53.45 (-5.21)
Leishmaniasis (Kala-Azar) - Pipeline Review 2015
M2 - Fri Jan 29, 9:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/4vk3jg/leishmaniasis) has announced the addition of the "Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Leishmaniasis (Kala-Azar) Overview - Therapeutics Development - Pipeline Products for Leishmaniasis (Kala-Azar) - Overview - Pipeline Products for Leishmaniasis (Kala-Azar) - Comparative Analysis - Leishmaniasis (Kala-Azar) - Therapeutics under Development by Companies - Leishmaniasis (Kala-Azar) - Therapeutics under Investigation by Universities/Institutes - Leishmaniasis (Kala-Azar) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Leishmaniasis (Kala-Azar) - Products under Development by Companies - Leishmaniasis (Kala-Azar) - Products under Investigation by Universities/Institutes - Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development Companies Mentioned: - Advinus Therapeutics Ltd. - Anacor Pharmaceuticals, Inc. - BioLingus AG - Dafra Pharma International Ltd. - iCo Therapeutics Inc. - Merck KGaA - Mologen AG - Nanomerics Ltd - Sanofi - Takeda Pharmaceutical Company Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/4v...shmaniasis
ANAC: 53.45 (-5.21)
BUYINS.NET: EUFN, CLDT, FN, QLIK, ANAC, ELA Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Jan 19, 6:36AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Ishares MSCI Europe Financials Sector Index Fund (NASDAQ:EUFN), Chatham Lodging Trust (NYSE:CLDT), First National Financial Services Ltd (NYSE:FN), Qlik Technologies Inc (NASDAQ:QLIK), Anacor Pharmaceuticals Inc (NASDAQ:ANAC), (NYSE:ELA) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
CLDT: 21.43 (+0.18), ELA: 25.28 (unch), FN: 32.35 (-0.24), QLIK: 28.92 (+0.39), EUFN: 17.91 (-0.10), ANAC: 53.45 (-5.21)
6 Drug Stocks That Look to Beat the Market in 2016
Zacks Equity Research - Zacks Investment Research - Mon Jan 18, 3:50PM CST
Don't miss these drug stocks that look to beat the market in 2016.
UTHR: 111.43 (+1.49), PFE: 29.64 (-0.43), AERI: 12.16 (+0.02), ANAC: 53.45 (-5.21), OHRP: 3.21 (+0.05), INFI: 5.27 (+0.12), PCRX: 52.98 (+2.12)
